Diagnostic Testing for
    Alzheimer’s Disease

    Home
    Industry-Leading Diagnostic Testing for Alzheimer’s Disease

    We empower healthcare professionals with cutting-edge solutions for neurological testing, focusing on early, accurate detection of neurodegenerative diseases—most notably Alzheimer’s disease. Our new ALZpath™ p-Tau 217 blood test offers unmatched diagnostic accuracy and is now available for clinical use in our CAP/CLIA-certified laboratory.

    Why Early Detection Matters

    Alzheimer’s disease (AD) is a progressive neurodegenerative disorder caused by the buildup of extracellular amyloid-beta (Aβ) plaques and intracellular neurofibrillary tangles of hyperphosphorylated tau (p-Tau). These changes can begin years before symptoms appear, making early biomarker-based detection critical for timely diagnosis and care.

    p-Tau 217: A Breakthrough Biomarker

    Tau proteins help stabilize nerve cell structures, but when they become hyperphosphorylated, they aggregate into tangles that disrupt brain function. Among tau isoforms, p-Tau 217 has proven to be one of the most reliable indicators of Alzheimer’s disease. Elevated p-Tau 217 levels in plasma and cerebrospinal fluid (CSF) strongly correlate with disease progression and align closely with amyloid and tau PET imaging results.

    About the ALZpath™ p-Tau 217 Test

    Our ALZpath™ p-Tau 217 assay matches the performance of CSF-based testing while offering the convenience of a blood draw. In clinical validation studies, it achieved high diagnostic accuracy in identifying amyloid PET-positive individuals (AUC = 0.932).

    Test Specifications:

    • Sample Type: EDTA plasma
    • Turnaround Time: 3–10 business days
    • Laboratory Certification: CAP/CLIA-certified

    Revolutionizing Preventive Alzheimer’s Testing

    We also offer the Lumipulse G p-Tau 217/β-Amyloid 1-42 Plasma Ratio—a test designed for adults aged 50 and older who are experiencing symptoms of cognitive decline. This assay detects amyloid plaque buildup early, enabling intervention before significant disease progression.

    Accessible, Patient-Focused Testing

    Our services are designed for both patients and healthcare providers, with a streamlined ordering process that ensures efficiency, clarity, and convenience from start to finish.

    Together, we can change the future of Alzheimer’s diagnosis—making early detection more accurate, accessible, and actionable.
    Book Your Appointments
    Book Your Appointments